Based on the excerpt you supplied from the Business Wire release, Bicycle Therapeutics plc’s Q2 2025 earnings announcement focuses on reporting the financial results for the quarter ended June 30 2025 and on providing “recent corporate updates.” The portion of the press‑release that was included in your message does not contain any language indicating that the company issued an updated financial outlook, revenue guidance, cash‑burn projection, or any other forward‑looking quantitative guidance for the remainder of 2025 (e.g., for the full‑year 2025 or for the subsequent quarters).
What the release does say (as far as the excerpt shows):
- It reiterates the company’s strategic focus on its “proprietary bicyclic peptide (Bicycle®) technology.”
- It notes that the company “continues to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next‑generation…” (the sentence is cut off).
- No sentences or bullet points about updated forecasts, anticipated cash burn, expected product milestones, or any revised revenue or expense expectations are present in the provided text.
Conclusion:
From the information you provided, Bicycle Therapeutics did not disclose any updated guidance or outlook for the remainder of 2025 in this particular news release. If you need the exact guidance (if any) that may have been included elsewhere in the full press release, you would need to consult the complete filing or a more complete excerpt of the announcement.